EGFR and non-small cell lung carcinoma: As the third-generation EGFR tyrosine kinase inhibitors (TKIs) and the first-line therapy for advanced EGFR-mutated NSCLC [10,11], osimertinib can selectively inhibit EGFR that has activating mutations and/or the T790M resistance mutation for the targeted therapy of LUAD [7,12,13,14].